Cytek Biosciences (NasdaqGS:CTKB) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker2Thank you, operator. Earlier today, Cytek Biosciences released financial results for the fourth quarter and year ended December 31, 2025. If you haven't received this news release or you'd like to be added to the company's distribution list, please send an email to investors@cytekbio.com. A copy of the news release is also available on the investor relations section of Cytek's website at investors.cytekbio.com. Joi ...

FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Total revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at CytekTotal revenue for the full year 20 ...

FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Cytek management is scheduled to participate in a hybrid presentation and fireside chat on Wednesday, March 4th at 8:10 a.m. Pacific Time / 11:10 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “In ...

Core Viewpoint - Cytek Biosciences, Inc. will report its financial results for Q4 and full year 2025 on February 26, 2026, with a conference call to discuss the results and outlook [1]. Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution, high-content, and high-sensitivity cell analysis [2]. - The company's product offerings include core FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Aurora™ Evo systems, as well as the Cytek Orion™ reagent cocktail preparation system and Enhanced Small Particle™ (ESP™) detection technology [2]. - Cytek is headquartered in Fremont, California, and has a global presence with offices and distribution channels [2]. Product Usage - Cytek's products are intended for research use only, with the exception of the Northern Lights-CLC system and certain reagents available for clinical use in China and the European Union [3]. Information Distribution - Cytek utilizes various channels, including its website, LinkedIn page, and X account, to distribute information about the company, products, and financial announcements, complying with Regulation FD [4].

Investor Presentation January 2026 Safe Harbor Statement This presentation and the related conference call and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's expected revenue for the fourth quarter and full year ended December 31, 2025; Cytek's market position and long-term market expansion opportunities; Cytek's business, product and operational goals and strategies; and Cytek's opp ...

Core Insights - Cytek Biosciences, Inc. has been recognized as one of America's Growth Leaders of 2026 by TIME in partnership with Statista, highlighting its exceptional growth, financial stability, and stock performance over the past five years [1][14]. Company Overview - Cytek Biosciences specializes in high-parameter cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver innovative tools for laboratories [7]. - The company is headquartered in Fremont, California, and has a global presence with offices and distribution channels [7]. Financial Performance - The inclusion in TIME's list signifies Cytek's strong financial foundation and sustained business expansion, reflecting its ability to deliver long-term value [2][5]. - Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, indicating their significant impact on global research [4]. Innovation and Technology - Cytek's mission is to make high-parameter cell analysis more accessible and cost-effective, addressing urgent challenges in health and science, such as cancer research and vaccine development [3]. - The company's FSP technology sets a new standard in flow cytometry, enhancing the precision and sensitivity of cell analysis [3][7]. Market Position - Being named to the Growth Leaders list places Cytek among an elite group of companies demonstrating resilience and a forward-looking approach in a dynamic market [5].

Core Insights - Cytek Biosciences, Inc. has been recognized in TIME's 2026 list of America's Growth Leaders, highlighting its exceptional growth, financial stability, and stock performance over the past five years [1][5] - The inclusion in this list signifies Cytek's strong financial foundation and sustained business expansion, particularly in delivering innovative cell analysis solutions [2][5] Company Overview - Cytek Biosciences specializes in high-parameter cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP®) technology to enhance the precision and sensitivity of cell analysis [6] - The company aims to make high-parameter cell analysis more accessible and cost-effective for laboratories of all sizes, addressing urgent challenges in health and scientific research [3][4] Industry Impact - Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, demonstrating their significant impact on global research [4] - The company's innovations support advancements in cancer research, cell and gene therapies, vaccine development, and responses to emerging diseases [3][4]

Core Insights - Cytek Biosciences, Inc. has been awarded the title of Drug Discovery Solution of the Year for its Cytek Muse Micro cell analyzer at the 2025 BioTech Breakthrough Awards, recognizing its innovative contributions to the life sciences and biotechnology sectors [1][3][10] Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, focusing on high-resolution, high-content, and high-sensitivity cell analysis through its patented Full Spectrum Profiling™ (FSP) technology [5] - The company is headquartered in Fremont, California, and has a global presence with offices and distribution channels [5] Product Highlights - The Cytek Muse Micro cell analyzer enhances the original Guava Muse system, offering a compact, cost-effective, and multifunctional platform that simplifies flow cytometry while maintaining accuracy and versatility [2][4] - Applications of the Muse Micro system include cell counting, cell health and viability assessment, apoptosis, immunophenotyping, immune cell monitoring, and fluorescent protein analysis [2] Market Impact - The Muse Micro system aims to democratize access to sophisticated cell analysis, making it more accessible for smaller labs and resource-limited facilities, which traditionally faced barriers due to the complexity and cost of traditional flow cytometry systems [3][4]

Core Insights - Cytek Biosciences, Inc. is launching a two-part research support initiative to enhance accessibility to cell analysis amid reduced government funding and global economic challenges [1][2][3] Group 1: Initiative Details - The first phase involves awarding a three-laser Cytek Northern Lights™ flow cytometer, which utilizes Full Spectrum Profiling™ technology for versatile assays [2][3] - The second phase will introduce a grant program for funding eligible research projects, assessed through a merit-based process overseen by a scientific advisory board [3] Group 2: Collaboration and Impact - Cytek's initiatives are part of an ongoing collaboration with the International Society for Advancement of Cytometry (ISAC) to improve access to advanced cytometry tools globally [4] - A previous donation of a Cytek Northern Lights™ flow cytometer to a lab in Argentina exemplifies the impact of collaboration in empowering scientists in underserved communities [4] Group 3: Company Commitment - Cytek is dedicated to democratizing access to flow cytometry, ensuring that labs of all sizes and budgets can utilize advanced tools for cellular insights [5] - The company emphasizes the importance of community engagement alongside technological innovation to benefit the entire scientific community [5][7]

Core Insights - Cytek Biosciences, Inc. will report its financial results for Q3 2025 on November 5, 2025, after market close, followed by a conference call to discuss the results and outlook [1] Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [2] - The company's product offerings include FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Orion™, along with various reagents and software, providing a comprehensive suite of solutions for customers [2] - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [2] Product Usage - Cytek's products are intended for research use only, with specific exceptions for clinical use in China and the European Union for certain systems and reagents [3] Information Distribution - The company utilizes multiple channels, including its website, LinkedIn, and X account, to disseminate material information and comply with disclosure obligations under Regulation FD [4]